Remedy has successfully closed a targeted share issue of 1 million new stocks, resulting in a dilution of approximately 8% adding EUR 40 million in cash. We believe many institutional investors have been sitting on the “replacement bench” eager to invest for quite some time, due to the low free float in the stock. A less cautiously Remedy is a good thing we expect. With higher stakes comes higher returns most likely for a creative powerhouse such as Remedy.